Department of Basic and Clinical Neuroscience, Maurice Wohl Clinical Neuroscience Institute, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.
Department of Biostatistics and Health Informatics, Institute of Psychiatry, Psychology and Neuroscience, King's College London, London, SE5 8AF, UK.
Ann Clin Transl Neurol. 2024 Jul;11(7):1775-1786. doi: 10.1002/acn3.52083. Epub 2024 May 22.
Neurofilament heavy-chain gene (NEFH) variants are associated with multiple neurodegenerative diseases, however, their relationship with ALS has not been robustly explored. Still, NEFH is commonly included in genetic screening panels worldwide. We therefore aimed to determine if NEFH variants modify ALS risk.
Genetic data of 11,130 people with ALS and 7,416 controls from the literature and Project MinE were analysed. We performed meta-analyses of published case-control studies reporting NEFH variants, and variant analysis of NEFH in Project MinE whole-genome sequencing data.
Fixed-effects meta-analysis found that rare (MAF <1%) missense variants in the tail domain of NEFH increase ALS risk (OR 4.55, 95% CI 2.13-9.71, p < 0.0001). In Project MinE, ultrarare NEFH variants increased ALS risk (OR 1.37 95% CI 1.14-1.63, p = 0.0007), with rod domain variants (mostly intronic) appearing to drive the association (OR 1.45 95% CI 1.18-1.77, p = 0.0007, p = 0.003). While in the tail domain, ultrarare (MAF <0.1%) pathogenic missense variants were also associated with higher risk of ALS (OR 1.94, 95% CI 0.86-4.37, p = 0.039), supporting the meta-analysis results. Finally, several tail in-frame deletions were also found to affect disease risk, however, both protective and pathogenic deletions were found in this domain, highlighting an intricate architecture that requires further investigation.
We showed that NEFH tail missense and in-frame deletion variants, and intronic rod variants are risk factors for ALS. However, they are not variants of large effect, and their functional impact needs to be clarified in further studies. Therefore, their inclusion in routine genetic screening panels should be reconsidered.
神经丝重链基因(NEFH)变体与多种神经退行性疾病有关,但它们与 ALS 的关系尚未得到充分探索。尽管如此,NEFH 通常被纳入全球遗传筛查面板。因此,我们旨在确定 NEFH 变体是否会改变 ALS 的风险。
对文献中和 MinE 项目中 11130 名 ALS 患者和 7416 名对照者的遗传数据进行分析。我们对报告 NEFH 变体的已发表病例对照研究进行了荟萃分析,并对 MinE 全基因组测序数据中的 NEFH 变体进行了分析。
固定效应荟萃分析发现,NEFH 尾部的罕见(MAF<1%)错义变体增加了 ALS 的风险(OR 4.55,95%CI 2.13-9.71,p<0.0001)。在 MinE 项目中,超罕见的 NEFH 变体增加了 ALS 的风险(OR 1.37,95%CI 1.14-1.63,p=0.0007),其中杆状结构域变体(主要为内含子)似乎驱动了这种关联(OR 1.45,95%CI 1.18-1.77,p=0.0007,p=0.003)。而在尾部,超罕见(MAF<0.1%)致病性错义变体也与 ALS 风险增加相关(OR 1.94,95%CI 0.86-4.37,p=0.039),支持荟萃分析结果。最后,还发现几个尾部的框内缺失也会影响疾病风险,但在该区域既发现了保护性缺失,也发现了致病性缺失,这突显了一个需要进一步研究的复杂结构。
我们表明,NEFH 尾部的错义和框内缺失变体以及内含子的杆状结构域变体是 ALS 的危险因素。然而,它们不是影响较大的变体,其功能影响需要在进一步的研究中阐明。因此,在常规遗传筛查面板中纳入这些变体应重新考虑。